EA201591199A1 - Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение - Google Patents

Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение

Info

Publication number
EA201591199A1
EA201591199A1 EA201591199A EA201591199A EA201591199A1 EA 201591199 A1 EA201591199 A1 EA 201591199A1 EA 201591199 A EA201591199 A EA 201591199A EA 201591199 A EA201591199 A EA 201591199A EA 201591199 A1 EA201591199 A1 EA 201591199A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
benzapetine
sertonin
application
receptor ligands
Prior art date
Application number
EA201591199A
Other languages
English (en)
Other versions
EA026397B1 (ru
Inventor
Майк Робардж
Джон Харрингтон
Дэвид Герриш
Джон Меком
Original Assignee
ЭйБиТи ХОЛДИНГ КОМПАНИ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйБиТи ХОЛДИНГ КОМПАНИ filed Critical ЭйБиТи ХОЛДИНГ КОМПАНИ
Publication of EA201591199A1 publication Critical patent/EA201591199A1/ru
Publication of EA026397B1 publication Critical patent/EA026397B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение в целом относится к ряду соединений, к фармацевтическим композициям, содержащим указанные соединения, а также к применению указанных соединений и композиций в качестве терапевтических агентов. В частности, соединения согласно изобретению представляют собой соединения бензазепина. Указанные соединения представляют собой лиганды серотониновых рецепторов (5-HT) и подходят для лечения заболеваний, нарушений и патологических состояний, при которых требуется модуляция активности серотониновых рецепторов (5-HT) (например, зависимость, тревога, депрессия, ожирение и др.).
EA201591199A 2012-12-21 2013-12-23 Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение EA026397B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745241P 2012-12-21 2012-12-21
PCT/US2013/077501 WO2014100815A2 (en) 2012-12-21 2013-12-23 Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof

Publications (2)

Publication Number Publication Date
EA201591199A1 true EA201591199A1 (ru) 2015-10-30
EA026397B1 EA026397B1 (ru) 2017-04-28

Family

ID=50979422

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591199A EA026397B1 (ru) 2012-12-21 2013-12-23 Бензазепины в качестве лигандов серотониновых 5-ht-рецепторов и их применение

Country Status (14)

Country Link
US (1) US9284277B2 (ru)
EP (1) EP2938345B1 (ru)
JP (1) JP2016503808A (ru)
KR (1) KR20150108840A (ru)
CN (1) CN105101967B (ru)
AU (1) AU2013364022A1 (ru)
BR (1) BR112015014674A2 (ru)
CA (1) CA2894552A1 (ru)
EA (1) EA026397B1 (ru)
IL (1) IL239206B (ru)
MX (1) MX2015008034A (ru)
SG (1) SG11201504749TA (ru)
WO (1) WO2014100815A2 (ru)
ZA (1) ZA201503955B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN105859536B (zh) * 2016-05-06 2018-08-14 蚌埠中实化学技术有限公司 一种3,4-二氟苯甲醛的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255445A (en) * 1980-03-07 1981-03-10 Smithkline Corporation 8-Hydroxy-6,7-(2-methyl-2,3-dihydrofuro)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA821020B (en) 1981-02-18 1983-10-26 Thomae Gmbh Dr K Azepine derivatives, process for their preparation and pharmaceutical compositions thereof
DE3230696A1 (de) 1982-08-18 1984-02-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue thieno-thiazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8800891D0 (en) 1988-01-15 1988-02-17 Lilly Industries Ltd Pharmaceutical compounds
GB9025890D0 (en) 1990-11-28 1991-01-09 Lilly Industries Ltd Pharmaceutical compounds
EP0596125A4 (en) 1991-12-26 1994-10-05 Yoshitomi Pharmaceutical Condensed thiophene compound and pharmaceutical use thereof.
US5532240A (en) 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
DK26793D0 (da) * 1993-03-10 1993-03-10 Novo Nordisk As Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling
US5998433A (en) 1994-10-11 1999-12-07 Takeda Chemical Industries, Ltd. Condensed compounds, their production and use
EP1343796A4 (en) * 2000-10-23 2005-01-12 Smithkline Beecham Corp COMPOUNDS AND METHODS
CA2498106A1 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
JP4920409B2 (ja) 2003-06-17 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド ３−ベンズアゼピンを調製する方法
AU2004283196B2 (en) 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
WO2005042491A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CA2565683C (en) * 2004-06-30 2013-04-02 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
CN102482292B (zh) * 2009-04-23 2017-07-18 Abbvie 公司 5‑ht受体的调节剂和其使用方法

Also Published As

Publication number Publication date
EP2938345A4 (en) 2016-10-05
EP2938345A2 (en) 2015-11-04
WO2014100815A2 (en) 2014-06-26
US20140194411A1 (en) 2014-07-10
EP2938345B1 (en) 2018-08-22
EA026397B1 (ru) 2017-04-28
WO2014100815A3 (en) 2014-08-21
SG11201504749TA (en) 2015-07-30
BR112015014674A2 (pt) 2017-07-11
IL239206A0 (en) 2015-07-30
CN105101967B (zh) 2019-06-28
CN105101967A (zh) 2015-11-25
IL239206B (en) 2018-12-31
KR20150108840A (ko) 2015-09-30
ZA201503955B (en) 2016-05-25
JP2016503808A (ja) 2016-02-08
US9284277B2 (en) 2016-03-15
MX2015008034A (es) 2016-03-07
CA2894552A1 (en) 2014-06-26
AU2013364022A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
EA201201541A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ
EA201391674A1 (ru) Новые соединения, связывающие фарнезоидный x-рецептор (nr1h4) и модулирующие его активность
EA201400569A1 (ru) Новые производные циклогексиламина, обладающие агонистической активностью по отношению к бета-2 адренергическому рецептору и антагонистической активностью по отношению к мускариновому рецептору м3
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201391106A1 (ru) Новые гетероциклические производные
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
EA201270808A1 (ru) Новые формы рифаксимина и их применение
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
EA201790963A1 (ru) Противовирусные соединения
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU